Holen Sie sich die Stockscreener-App
38.30
0.24%
0.0681
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes - Stock Titan
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - Kalkine
Transcript : Definium Therapeutics, Inc.Special Call - marketscreener.com
After $1.23M sale, Definium Therapeutics (DFTX) holder plans another stock trade - Stock Titan
Stifel reiterates Buy on Definium Therapeutics stock, $60 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on Definium Therapeutics stock, $60 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Definium Therapeutics Announces New Employee Inducement Grants - The Chronicle-Journal
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72 - moomoo.com
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Stifel confident in Definium Therapeutics stock after management dinner By Investing.com - Investing.com Nigeria
Stifel confident in Definium Therapeutics stock after management dinner - Investing.com
SW Weekly: Why I Can't Buy Definium Following Phase 3 LSD Readout. (NASDAQ:DFTX) - Seeking Alpha
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Business Wire
Certain Common Shares of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
Certain Warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - Moomoo
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):